Celyad announced that the FDA has accepted the company’s Investigational New Drug, or IND, application for CYAD-101, the first non-gene edited allogeneic clinical program. The FDA has indicated that the Allo-SHRINK trial, evaluating the safety and clinical activity of CYAD-101 in patients with unresectable colorectal cancer in combination with standard chemotherapy, is allowed to proceed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.